Etiological drug treatment of human infection by Trypanosoma cruzi

Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.

Saved in:
Bibliographic Details
Main Authors: Levi,Guido Carlos, Lobo,Isa Maria Fraga, Kallás,Esper Georges, Amato Neto,Vicente
Format: Digital revista
Language:English
Published: Instituto de Medicina Tropical de São Paulo 1996
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0036-46651996000100007
record_format ojs
spelling oai:scielo:S0036-466519960001000072006-09-22Etiological drug treatment of human infection by Trypanosoma cruziLevi,Guido CarlosLobo,Isa Maria FragaKallás,Esper GeorgesAmato Neto,Vicente Chronic Chagas' disease Antiparasitic treatment Benznidazole Nifurtimox Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.info:eu-repo/semantics/openAccessInstituto de Medicina Tropical de São PauloRevista do Instituto de Medicina Tropical de São Paulo v.38 n.1 19961996-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007en10.1590/S0036-46651996000100007
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Levi,Guido Carlos
Lobo,Isa Maria Fraga
Kallás,Esper Georges
Amato Neto,Vicente
spellingShingle Levi,Guido Carlos
Lobo,Isa Maria Fraga
Kallás,Esper Georges
Amato Neto,Vicente
Etiological drug treatment of human infection by Trypanosoma cruzi
author_facet Levi,Guido Carlos
Lobo,Isa Maria Fraga
Kallás,Esper Georges
Amato Neto,Vicente
author_sort Levi,Guido Carlos
title Etiological drug treatment of human infection by Trypanosoma cruzi
title_short Etiological drug treatment of human infection by Trypanosoma cruzi
title_full Etiological drug treatment of human infection by Trypanosoma cruzi
title_fullStr Etiological drug treatment of human infection by Trypanosoma cruzi
title_full_unstemmed Etiological drug treatment of human infection by Trypanosoma cruzi
title_sort etiological drug treatment of human infection by trypanosoma cruzi
description Forty-nine American Trypanosomiasis (Chagas' disease) patients, with xenodiagnosis proven parasitemia were treated by the authors. Forty-one of these patients were given benznidazole, at dosages ranging from 5mg/kg/day to 8mg/kg/day, during a pre-established period of 60 days. In this group, 17 patients had an undetermined form of the disease, whereas 22 had cardiologic disease and 4 had digestive disease (two patients had a mixed form of the disease). Side effects were frequent, and led to the discontinuation of treatment in 17 patients. The follow-up period ranged from 1 to 20 years (mean follow-up period of 6 yrs. 7 mo). 26 (63.4%) of the patients became parasitemia-negative. The other eight patients were treated with nifurtimox, during 120 days, following a variable dose regime of 5mg/kg/day (initial dose) to 17 mg/kg/day (final dose). Six of them had severe side effects, and only one patient remained parasitemia-negative throughout the observation period (ranging from 1 to 18 years). Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable.
publisher Instituto de Medicina Tropical de São Paulo
publishDate 1996
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0036-46651996000100007
work_keys_str_mv AT leviguidocarlos etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi
AT loboisamariafraga etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi
AT kallasespergeorges etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi
AT amatonetovicente etiologicaldrugtreatmentofhumaninfectionbytrypanosomacruzi
_version_ 1756379664270491648